Janus kinase inhibitors in dermatology: Part II. A comprehensive review.
J Am Acad Dermatol
; 86(2): 414-422, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-1333530
ABSTRACT
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is implicated in the pathogenesis of a number of inflammatory dermatoses. Clinical trials and other studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here we review JAK inhibitors currently under investigation for the treatment of alopecia areata, vitiligo, sarcoidosis, necrobiosis lipoidica, granuloma annulare, and systemic lupus erythematosus with a special emphasis on safety and the implications of JAK inhibitors during the novel coronavirus 2019 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Diseases
/
Dermatology
/
Janus Kinase Inhibitors
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Am Acad Dermatol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS